Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
RNAC Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cartesian Therapeutics, Inc.NASDAQ: RNAC
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $310K fell 83.0% year over year, behind the -6.7% change in trailing-twelve-month accounts payables. Over 3 fiscal years it compounded at +126.3% a year.
Context
- Accounts payables amounted to 38.1% of revenue in FY2025, up 30.6 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -83.0% toward the trailing-twelve-month pace of -6.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.07M USD
- Year-over-year change
- +136.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.07M | +136.4% |
| FY2024 | 2024-12-31 | (2.93M) | -203.3% |
| FY2023 | 2023-12-31 | 2.83M | +2980.4% |
| FY2022 | 2022-12-31 | 92K | +142.0% |
| FY2021 | 2021-12-31 | (219K) | — |
Accounts Payables vs competitors
How RNAC compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.7% is the 6th highest of 8, against a peer median of +37.6%.
- Accounts payables amounts to 25.0% of revenue for RNAC, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $3.31M USD | +280.1% | +21.9% | — |
| LTM Mar 2026 | $3.06M USD | -161.7% | — | 9.3% | |
| FY2025 | €2.46M EUR | — | -11.4% | 54.8% | |
| LTM Mar 2026 | $2.31M USD | +37.6% | +78.4% | 16.0% | |
| LTM Mar 2026 | $2.01M USD | +6.4% | +97.6% | — | |
| LTM Mar 2026 | $977.56K USD | -52.1% | — | 1.9% | |
| LTM Mar 2026 | $443K USD | -6.7% | +126.3% | 25.0% | |
| LTM Mar 2026 | $365.18K USD | — | — | — | |
| LTM Mar 2026 | $325K USD | +38.3% | -33.1% | 550.8% | |
| LTM Mar 2026 | $262K USD | +132.6% | -50.3% | — | |
| Peer median (excluding RNAC) | — | +37.6% | +5.2% | 16.0% | |
Competitors are the stored peer set for RNAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (25.69M) | 35.38M | (219.71M) | (77.42M) | (130.3M) |
| Depreciation & Amortization | 1.25M | 1.29M | 843K | 1.15M | 2.96M |
| Deferred Income Tax | 2.4M | (21.4M) | (19M) | 287K | (9.19M) |
| Stock-Based Compensation | 7.72M | 11.19M | 22.52M | 6.58M | 10.52M |
| Change in Working Capital | (48.19M) | (60.38M) | 4.97M | (5.79M) | (8.06M) |
| Accounts Receivables | (2.69M) | 3.32M | 907K | 7.98M | (243K) |
| Inventory | 211K | 920K | 0 | 0 | 0 |
| Accounts Payables | (219K) | 92K | 2.83M | (2.93M) | 1.07M |
| Other Working Capital | (45.5M) | (64.71M) | 1.23M | (10.84M) | (8.89M) |
| Other Non-Cash Items | 2.13M | 2.29M | 159.21M | 51.52M | 60.14M |
| Operating Cash Flow | (60.38M) | (31.63M) | (51.16M) | (23.67M) | (73.94M) |
| Capital Expenditures | (1.09M) | (1.2M) | (206K) | (9.09M) | (5.45M) |
| Acquisitions (Net) | 0 | 0 | 6.56M | 351K | 0 |
| Purchases of Investments | (32.46M) | (33.5M) | 0 | 0 | 0 |
| Sales of Investments | 16.4M | 19.7M | 28.25M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (17.14M) | (15M) | 34.61M | (8.74M) | (5.45M) |
| Debt Repayment | 0 | 0 | (27.46M) | 0 | 0 |
| Common Stock Issued | 51.96M | 38.98M | 0 | 124.44M | (301K) |
| Common Stock Repurchased | 0 | 0 | (6.17M) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 939K | 235K | 231K | 3.99M | (7.75M) |
| Financing Cash Flow | 52.9M | 39.22M | (13.15M) | 168.43M | (8.06M) |
| Effect of Forex Changes | (3K) | 20K | (53K) | (21K) | 45K |
| Net Change in Cash | (24.63M) | (7.4M) | (29.75M) | 135.99M | (87.41M) |
| Free Cash Flow | (61.47M) | (32.83M) | (51.37M) | (32.77M) | (79.4M) |
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
Intrinsic Alpha fair value
Locked
Current Price
$6.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.